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Adhesion molecules play an integral role in tumour growth, inva-
sion and metastasis and have been shown to influence the host
immune response to malignant cells. Tumour progression is asso-
ciated with changes in the expression of cellular adhesion mole-
cules which accompany the disaggregation of individual cells
from the primary tumour and their penetration through the base-
ment membrane, migration through the blood or lymph vessels,
and attachment to a distant site (Johnson, 1991). Adhesion mole-
cules are also required to provide ‘co-stimulatory’ antigen-
independent interactions between leukocytes and target cells in the
initiation of a cellular immune response against tumour cells
(Springer, 1990). 
Intercellular adhesion molecule-1 (ICAM-1 CD54) is a single-
chain, 90 kDa inducible cell-surface glycoprotein and a member of
the immunoglobulin supergene family which mediates many adhe-
sion-dependent cell–cell interactions. It is constitutively expressed
on haemopoietic cells such as tissue macrophages, monocytes, B-
cells, activated T-cells and germinal centre dendritic cells. ICAM-1
expression can also be induced by inflammatory cytokines such as
IFN-γ , IL1-β and TNF-α in non-haemopoietic cells including
vascular endothelium, thymic epithelium and dermal fibroblasts
(Springer et al, 1987; Springer, 1990). ICAM-1 and -2 and their
counter-receptors, the cell-surface integrins lymphocyte-function-
associated antigen-1 (LFA-1) and the complement receptor type-3
(CR-3, Mac-1, CD11a/CD18) have been shown to be essential for
most cell–cell interactions in the immune response (Diamond et al,
1991), including MHC-restricted antigen presentation, cell prolif-
eration induced by antigens and mitogens, T-cell mediated cyto-
toxicity and transvascular lymphocyte migration. 
Ovarian adenocarcinoma is the sixth most common cancer among
women worldwide, and the leading cause of death from gynaecolog-
ical neoplasias (Parkin et al, 1999). Ovarian adenocarcinomas arise
from the surface epithelium of the ovary (OSE), but the molecular
events that drive the initiation and progression of ovarian adenocar-
cinoma are not well defined. The lack of symptoms during the early
stages of the disease results in the majority of women presenting
with advanced tumours that do not respond well to treatment. We
investigated changes in the expression of a panel of 588 known
human genes in ovarian adenocarcinoma cell lines compared with
immortalised human ovarian surface epithelial (HOSE) cell using a
cDNA array (Arnold et al, 2001). This revealed that ICAM-1
expression was decreased in ovarian adenocarcinoma cell lines
compared with the HOSE cells. The aim of the present study was to
investigate the extent of the down-regulation of ICAM-1 expression
in a larger panel of ovarian adenocarcinoma cell lines and primary
tumours at both the RNA and protein levels, and to determine
whether expression was related to patient survival. 
METHODS 
Cell lines, ovarian surface epithelium cultures and
primary tumours 
Human ovarian surface epithelial cell lines (HOSE) 17.1 and 1.1,
immortalised with a retroviral vector expressing human papillo-
mavirus oncogenes (Tsao et al, 1995) were maintained in a
medium composed of 1:1 M199:MCDB105 with 10% FCS. The
HEY ovarian adenocarcinoma cell line was maintained in MEMα
medium with 10% FCS (Buick et al, 1985). The remaining ovarian
adenocarcinoma cell lines–OAW 42 (Wilson, 1984), PEO1 (Wolf
et al, 1987), PEO14 (Langdon et al, 1988), JAM (Ward et al,
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1979), CAOV3 (Wong et al, 1999), OVCAR-3 (Hamilton et al,
1983) and 27/87 (derived by T Hurst) – were all maintained in
RPMI 1640 with 10% FCS. Cells were harvested for RNA isola-
tion at about 80% confluence. The cell lines OAW 42, PEO1,
PEO14, JAM, SKOV3 and COLO316 were derived from serous
tumours, and 27/87 was from an endometrioid tumour. The histo-
logical types of the tumours from which the cell lines HEY,
CAOV3 and OVCAR3 were derived are unknown. 
Primary cultures of human ovarian surface epithelial (OSE)
cells were prepared according to the method of Kruk et al (1990).
Epithelial cells were obtained by scraping contaminating stromal
cells away from proliferating epithelial sheets and were cultured in
1:1 MCDB105: Medium 199 with Earles’ salts, supplemented
with 20 ng ml–1 epidermal growth factor, 400 ng ml–1 hydrocorti-
sone and 15% fetal calf serum. Their distinctive cellular
morphology was used to confirm that the cultures were epithelial
cells. In one case, RNA was extracted directly from the peeled
epithelial cells without culturing. 
Ovarian adenocarcinomas were obtained from 44 patients under-
going surgery. There were 35 serous, 6 endometrioid, one muci-
nous and 2 clear-cell tumours. There were 43 malignant tumours
and the other was of low malignant potential (LMP). All patients
were staged at laparotomy, in accordance with the recommenda-
tions of the International Federation of Gynaecology and Obstetrics
(FIGO). Of the malignant tumours, one was FIGO stage 1, 4 stage
2, 33 stage 3 and 5 stage 4. There were two grade 1–2, 11 grade 2,
10 grade 2/3, 17 grade 3, one grade 3–4, and 2 that were not graded.
Clinicopathological data for these tumours are summarised in Table
2. Constitutional DNA was available in all cases from peripheral
blood. RNA was available from a subset of 34 tumours. 
Isolation of DNA and RNA 
Tumour tissue was dissected free from necrotic tissue and connec-
tive tissue, and mechanically dispersed prior to collagenase treat-
ment (0.1 mg ml–1 in Hanks balanced salt solution). Erythrocytes
and necrotic cells were removed with ficoll-paque, and genomic
DNA was extracted by the salting-out method as described else-
where (Chenevix-Trench et al, 1992). Total RNA was extracted
from fresh primary tumours and sub-confluent cultured cell lines
using Tri-reagent (Sigma), following the manufacturer’s instruc-
tions. PolyA + RNA was prepared from total RNA using Dynabeads
(Dynal) according to the recommended protocol. 
Northern blot analysis 
RNA was denatured and electrophoresed on a formaldehyde-
agarose gel and transferred to a nylon membrane (Amersham
Hybond N+) by capillary blotting overnight according to standard
protocols (Sambrook et al, 1989). The RNA was then fixed to the
membrane by UV irradiation. Probes were prepared from RT-PCR
products by random priming (Amersham Megaprime) and
hybridization was carried out for 2 hours in ExpressHyb solution
(Clontech. Inc.) at 65˚C (for random primed probes) before a stan-
dard washing procedure. 
Semi-quantitative RT-PCR 
cDNA synthesis was performed on 1 µ g of total RNA in a volume
of 20 µ l using SuperScript II reverse transcriptase (Gibco BRL)
according to the manufacturer’s protocol. PCR was carried out on
1 µ l of this cDNA in a volume of 20 µ l incorporating 33P-dATP
using standard PCR cycling conditions. To ensure quantitation was
assessed only on amplified cDNA, all primer pairs were designed
to span at least one intron. The ICAM-1 primers used for the 5-
aza-2′ -deoxycytidine treated cell lines (CCAACCTCACCGTG-
GTGCTGCTCCG and GCAGTGTCTCCTGGCTCTGGTTCC)
amplify a 479 bp product from cDNA. The ICAM-1 primers used
for the primary tumours and cell lines (AAGCTTGCAAC-
CTCAGCCTCGCTATGG and CGGAGCAGCACCACGGT-
GAGGTTGG) amplify a 480 bp product from cDNA. The β -actin
primers used (CGTGACATTAAGGAGAAGCTGTGC and
CTCAGGAGGAGCAATGATCTTGAT) amplify a 375 bp product
from cDNA. Multiplex PCR was carried out and 5 µ l of product
removed at cycles 25, 29, 33 and 37 and the products run on a
denaturing acrylamide gel prior to autoradiography. The autoradi-
ogram showing products after 29 cycles of amplification was
scanned and analysed by densitometry for band intensity. The
value for the ICAM-1 band was then expressed as a percentage of
the corresponding band for β -actin after subtracting background
values. The ICAM-1 value for the HOSE 17.1 internal control was
then adjusted to 100 and all other values adjusted accordingly. 
Immunohistochemistry 
Normal ovaries (5) and ovarian adenocarcinomas (20) were
embedded in OCT compound (Miles Inc, USA), snap frozen in
liquid nitrogen, and stored at –70˚C until sectioning. Cultured cell
lines were harvested by scraping, were washed in PBS and
embedded as a dense suspension in OCT and frozen as above.
Serial sections (7 µ m) were air-dried and fixed in acetone at room
temperature for 10 minutes. After rehydration with tris-buffered
saline (TBS), pH 7.4, endogenous peroxidase activity was blocked
by incubation in 1% H2O2 0.1% NaN3 in TBS for 10 minutes,
followed by blocking non-specific antibody binding by incubation
in 4% skim milk powder in TBS for 15 minutes and normal goat
serum for 20 minutes. The anti-ICAM-1 monoclonal antibody
(Immunotech clone 84H10) was then applied overnight at 0.2 µ g
ml–1. The slides were then incubated in biotinylated goat anti-
rabbit immunoglobulin (Zymed Corp, San Francisco) for 15
minutes, followed by streptavidin horseradish peroxidase (Zymed)
for 8 minutes. Slides were washed 3 times in TBS for 5 minutes
between all steps. One serial section was processed and stained as
above but the primary antibody was omitted as a negative control.
Finally, the sections were incubated with 3,3′ -diaminobenzidine
(0.05%) and H2O2 (0.18%) in tris-saline buffer for about 5 minutes
to produce a brown reaction product and the sections were coun-
terstained with haematoxylin, dehydrated in alcohol, cleared in
xylene and mounted. Staining of vascular endothelium was moni-
tored as a positive control. 
5-aza-2′ -deoxycytidine treatment of ovarian
adenocarcinoma cell lines 
Cell lines were plated at 20–30% confluence and treated 24 hours
later (day 0) with 0, 0.5 or 2.0 µ M 5-aza-2′ -deoxycytidine. Fresh
media containing the same concentration of 5-aza-2′ -deoxycyti-
dine was added on day 2 and cells were harvested for RNA extrac-
tion on day 5. 
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LOH was assessed at 19p13 with the D19S558 marker. PCR
amplification was carried out for 35 cycles in the presence of 33P-
dATP and PCR products were analysed on a denaturing polyacry-
lamide gel. LOH was scored conservatively as a substantial
reduction in the intensity of one allele by 2 independent observers
one of whom was blind with respect to the sample identity. 
Statistical analyses 
Survival curves, survival probabilities and estimated mean
survival times were calculated according to the Kaplan–Meier
method. The differences between the survival curves for the
ICAM-1-positive and ICAM-1-negative groups were evaluated
using the log-rank test. This was evaluated in 4 different ways.
Expression was assigned positive or negative by immunohisto-
chemistry according to whether there was greater than or less than
10% of tumour cells staining and whether there was greater than or
less than 25% of tumour cells staining. Expression was also
assigned positive or negative by RT-PCR according to whether
there was greater than or less than 1% that of HOSE 17.1 band
intensity and whether there was greater than or less than 10% that
of HOSE 17.1 band intensity. Fisher’s exact test was used to eval-
uate the association between ICAM-1 expression and LOH at
19p13 and the test for trend was used to examine for a relationship
between ICAM-1 expression and stage or grade. 
RESULTS 
Analysis of ICAM-1 mRNA expression in ovarian cancer
cell lines and primary tumours 
We have previously used a cDNA array containing 588 known
genes to compare gene expression in 3 ovarian adenocarcinoma
cell lines with a HOSE cell line (Arnold et al, 2001), which
showed that ICAM-1 expression was reduced in the ovarian
adenocarcinoma cell lines compared with the HOSE cell line. To
confirm this result, we performed semi-quantitative RT-PCR on a
series of 10 ovarian adenocarcinoma cell lines, an immortalised
HOSE cell line and uncultured OSE cells using β -actin as an
internal control (Figure 1 and Table 1). ICAM-1 was strongly
expressed in HOSE 17.1 cells, low-passage OSE cultures (data not
shown) and 3 ovarian adenocarcinoma cell lines (CAOV3, 27/87
and PEO14). Moderate levels of expression were observed in the
peeled OSE cells and the OVCAR3 cell line while the JAM, HEY
and COLO316 cell lines expressed low levels of ICAM-1. The
remaining cell lines, PEO1, OAW42 and SKOV3 did not express
ICAM-1. 
The expression of ICAM-1 mRNA in 2 HOSE cell lines and 9
ovarian adenocarcinoma cell lines was also examined by Northern
blot analysis (Figure 2 and Table 1). There were strong and compa-
rable levels of ICAM-1 expression in both of the HOSE cell lines.
In contrast, only one of the 9 ovarian adenocarcinoma cell lines
(CAOV3) expressed ICAM-1 at a similar level while another 4 cell
lines (JAM, COLO316, OVCAR3 and 27/87) had much weaker
levels of expression. No ICAM-1 expression was detected in the
PEO1, OAW42, HEY and SKOV3 cell lines. These results were
not inconsistent with those obtained by RT-PCR, although the cell
lines OVCAR3 and 27/87 appeared to express more RNA by the
more sensitive RT-PCR analysis than they did by Northern blot. 
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Figure 1 Analysis of ICAM-1 expression in immortalised HOSE cells,
peeled (uncultured) OSE cells and ovarian adenocarcinoma cell lines by 
RT-PCR. RT-PCR was carried out with β -actin as an internal control. The
autoradiograph shown in the upper panel represents 29 cycles of
amplification. In the lower panel, ICAM-1 expression is analysed as a
percentage of β -actin levels for each lane with HOSE 17.1 set at 100%
Table 1 ICAM-1 expression in HOSE and ovarian adenocarcinoma cell
lines 
Cell line RT-PCR Northern Immunostaining 
percent Intensity Percent 
HOSE 17.1 100 XXXX XXX 100 
HOSE 1.1 XXXX 
OSE 30.9 
PEO1 0.9 0 X 50 
OAW42 0.3 0 0 0 
JAM 7 X X 50 
HEY 11.8 0 0 0 
SKOV3 0.8 0 0 0 
COLO316 5.4 X 
CAOV3 91.4 XXXX X 10 
OVCAR3 41.4 X 0 0 
27/87 113.1 X 
PEO14 138.2 XX 100 
0 = no expression detected; X, XX and XXX = increasing levels of
expression. 
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Figure 2 Analysis of ICAM-1 expression in HOSE and ovarian
adenocarcinoma cell lines by Northern blotting. Each lane represents 2 µ g of
polyA + RNA. (A) Hybridisation with the ICAM-1 probe, (B) hybridisation with
the β -actin probe The levels of ICAM-1 expression were then investigated in a
series of 34 primary ovarian adenocarcinomas using semi-quanti-
tative RT-PCR (Figure 3 and Table 2). Most of the primary
tumours expressed very little or no ICAM-1 RNA. There were 19
tumours (56%) which expressed less than 5% and 30 (88%) which
expressed less than 25% of the amount expressed by the HOSE
17.1 cells. Only 2 tumours expressed comparable levels of ICAM-
1 message to the HOSE 17.1 cells. 
Immunohistochemical analysis of ICAM-1 in ovarian
cancer cell lines, normal ovaries and primary tumours 
ICAM-1 expression was also examined in cell lines and primary
tumours by immunohistochemistry. The HOSE 17.1 cells and a
panel of 8 ovarian adenocarcinoma cell lines, for which the mRNA
expression levels were known, were examined first (Table 1).
Strong expression was observed in all HOSE 17.1 and PEO14
cells. There was a reduction in both the number of positive cells
and the intensity of staining for the PEO1 (50% of cells positive),
JAM (50% cells positive) and CAOV3 (10% cells positive) cell
lines, while no staining was found in the OAW42, HEY, SKOV3
or OVCAR3 cells. When present, staining was most intense on the
plasma membrane, but was also evident in the cytoplasm. This
result generally correlated well with the mRNA expression data,
although the CAOV3 and OVCAR3 cells expressed less protein
and the PEO1 cells more protein than predicted from the RT-PCR
and Northern blot data. 
ICAM-1 protein expression was then investigated in 5 normal
ovaries and 20 primary ovarian tumours by immunostaining
(Figure 4 and Table 2). Strong expression was observed in all
ovarian surface epithelial cells, including surface invaginations
and epithelial inclusions present in some of the ovaries. The
staining was predominantly on the plasma membrane, where it
was more intense on the apical side, but was also present in the
cytoplasm (Figure 4A, B). Staining of vascular endothelium was
also observed. 
The ICAM-1 reactivity of the primary ovarian tumours varied
with respect to both percentage of positive cells and the inten-
sity of staining (Figure 4C, D). The majority of tumours (18/20,
90%) showed a reduced intensity of staining relative to the
surface epithelium of normal ovaries. There were no tumours
which were completely negative, and the intensity varied from
very weak to strong. The percentage of positive cells varied
from 1% in the LMP tumour to 100% of epithelial cells staining.
Almost 70% of cases (14/20) had fewer than half of cells
staining. Many of the tumours showed a heterogeneous pattern
of ICAM-1 expression with discrete groups of positive and
negative cells. The majority of the tumours (16/20, 80%)
showed stronger staining in the cytoplasm than on the plasma
membrane (Figure 4C, D) and there was a distinct pattern of
staining bordering groups of tumour cells for 6 (30%) of the
tumours (Figure 4E). 
Thirteen tumours were analysed by both RT-PCR and immuno-
staining, and there was generally a good correlation between
mRNA and protein expression data for these tumours. However,
there were 2 cases (6/93 and 25/94) in which little or no mRNA
was detected by RT-PCR and yet were positive by immuno-
staining. This may have been due to the fact that different portions
of the tumours were used for the RNA extraction and the
immunostaining, and these may have varied in the proportion of
tumour cells expressing ICAM-1. 
5-aza-2′ -deoxycytidine treatment of ovarian cancer cell
lines increases ICAM-1 expression levels 
To investigate whether methylation of promoter CpG islands
may be involved in the down-regulation of ICAM-1 expression
in ovarian adenocarcinomas, a panel of 8 ovarian adenocarci-
noma cell lines were treated with 2 different concentrations of
the de novo methyltransferase inhibitor 5-aza-2′ -deoxycytidine.
RNA was then extracted 5 days later for analysis of expression
by semi-quantitative RT-PCR (Figure 5). Treatment with 0.5 µ M
5-aza-2′ -deoxycytidine resulted in increased ICAM-1 expression
levels relative to untreated controls for all cell lines, with the
greatest levels of induction occurring in the OAW42 (14.8
times), OVCAR3 (11.6 times) and JAM (6.6 times) cell lines.
Treatment with 2 µ M 5-aza-2′ -deoxycytidine, which was toxic to
the HEY cells, also resulted in increased ICAM-1 expression
levels relative to untreated controls for all cell lines, but gener-
ally not to the same degree as treatment with 0.5 µ M 5-aza-2′ -
deoxycytidine. 
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Figure 3 Analysis of ICAM-1 expression in primary ovarian
adenocarcinomas by RT-PCR. RT-PCR was carried out with β -actin as an
internal control. HOSE 17.1 cells were included as a positive control. (A) 18
primary tumours from patients who underwent surgery from 1989 to 1992.
(B) 16 primary tumours from patients who underwent surgery from 1993 to
1994. In each case, the autoradiograph shown in the upper panel represents
29 cycles of amplification. In the lower panel, ICAM-1 expression is analysed
as a percentage of β -actin levels for each lane with HOSE 17.1 set at 100%Loss of heterozygosity analysis of the ICAM-1 locus at
19p13 
ICAM-1 is located on chromosome 19 at band p13.1 to 13.2 (Ropers
and Mohrenweiser, 1993). Loss of heterozygosity at 19p13 was
analysed in 29 of the cases for which ICAM-1 expression had been
characterised with the D19S558 microsatellite marker. LOH was
detected in 8 cases (28% of informative cases). ICAM-1 expression
was not associated with LOH at 19p13 for mRNA expression
defined by > 1% of that of the HOSE 17.1 cells (P = 0.32, Fisher’s
exact test), but there was a weak association when mRNA expres-
sion was defined by > 10% of that of the HOSE 17.1 cells (P =
0.05). It was noteworthy that all tumours with LOH expressed less
than 3% the level of ICAM-1 mRNA of the HOSE 17.1 cells. 
Correlation of ICAM-1 expression with
histopathological characteristics and survival 
There was no trend towards loss of expression with higher stage (P
= 0.5 and 1.0 for mRNA expression defined as > 1% or > 10% that
of the HOSE 17.1 cells, Test for Trend) or grade (P = 0.59 and
0.69, respectively, Test for Trend), nor was there any association
between expression and histological subtypes (P = 0.71 and 0.20
respectively, χ 2 test). 
There was a significant correlation between ICAM-1 expression
in tumour cells and survival of those patients when 10% or less of
tumour cells staining was scored as negative (P = 0.03). However,
there was no relationship between ICAM-1 expression and
survival when this analysis was performed scoring 25% or less of
Reduced ICAM-1 expression in ovarian adenocarcinomas 1355
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Table 2 ICAM-1 expression, 19p13 LOH status and clinico-pathological data for 45 primary ovarian adenocarcinomas 
Case Histo Stage Grade RT-PCR percent Immunostaining LOH 19p13 
Intensity Percent 
HOSE 17.1 100 XXX 100 
OSE 30.9 XXX 100 
69/89 SER 3 2 0.3 NL 
35/90 SER 3B 2–3 105.2 NL 
5/91 SER 3 2 3.4 NL 
16/91 SER 2 3 0 NL 
33/91 ENDO 4 3 0.7 L 
44/91 SER 3C 3 19.2 NL 
45/91 SER 3C NS 0.4 NL 
52/91 SER 2B 2 3.3 
59/91 SER 3 3–4 99.6 NL 
62/91 SER 3 3 2.3 
68/91 SER 3C 3 8.1 
3/92 SER 3 3 XX 0.5 NL 
4/92 SER 3B 3 1.2 XX 0.1 NL 
26/92 CCC 4 2 19.4 XX <10% NL 
39/92 SER 3 2 24.6 NL 
62/92 SER 3C 2–3 1.4 L 
66/92 ENDO 3C 3 9.5 XX 0.2 NL 
67/92 ENDO 1C 2–3 35 NL 
76/92 SER 3 2–3 2.8 L 
3/93 SER 3C 3 L 
4/93 SER 3 1–2 2.2 XX <10% L 
5/93 SER 3C 2–3 10 NL 
6/93 SER 3C 3 1.3 XX 0.6 L 
8/93 SER 3C 2–3 2 XXX 0.2 NL 
10/93 SER 3C 2–3 7.8 XXX 0.25 NL 
12/93 CCC 3 2–3 XX 1 NL 
13/93 SER 3C NS 23.8 NL 
21/93 SER 3C 2–3X X 1  
35/93 SER 3C 3 0.3 NL 
61/93 ENDO 4 2 0 L 
65/93 ENDO 3 2–3 NL 
75/93 SER 2C 3 2.4 XX 0.45 
83/93 SER 3 3 XX 0.6 
99/93 ENDO 4 3 1.1 X 0.2 NI 
101/93 SER 3C 2 XX 0.1 
108/93 SER 3C 2 13.7 XX 0.2 
130/93 SER 3 2 XX 0.8 
17/94 SER 2B 3 XX 0.3 
23/94 SER 3 3 12.6 XX 0.2 
25/94 SER 3C 2 0 XX 0.4 
30/94 MUC OLMP1 26.1 XX 0.01 
34/94 SER 3C 3 
70/94 SER 3C 1–2 0.6 L 
90/94 SER 4 2 16.9 
0 = no expression detected; X, XX and XXX = increasing levels of expression; NL = no loss; NI = not informative; L = loss;
NS = not specified. tumour cells staining as negative (P = 0.98), nor when scoring
tumours with either 1% or less (P = 0.47), or 10% or less (P =
0.22) of HOSE 17.1 mRNA expression as negative. 
DISCUSSION 
We have analysed the expression of ICAM-1 in ovarian surface
epithelial cells and cell lines, adenocarcinoma cell lines and
primary tumours. ICAM-1 was expressed in normal ovarian
epithelial cells, from which ovarian adenocarcinomas arise. This is
in contrast to normal breast, kidney (renal tubules), gastric,
pancreatic (acinar and ductal cells) and colorectal epithelia, which
do not express ICAM-1 (Tomita et al, 1990; Kaiserlian et al, 1991;
Koyama et al, 1992; Schwaeble et al, 1993; Shibata et al, 1996;
Ogawa et al, 1998). The level of ICAM-1 expression in the
immortalised HOSE cell lines was about 3-fold greater than that in
the peeled OSE cells. Expression was reduced in the majority of
ovarian adenocarcinoma cell lines and primary tumours at both the
RNA and protein levels relative to both OSE cells and HOSE cell
lines. This suggests that down-regulation of ICAM-1 expression is
a common event in the development of ovarian adenocarcinoma
and may be of selective advantage to these cells. 
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Figure 4 Immunostaining for ICAM-1 in normal ovaries and primary ovarian tumours. (A, B) Normal ovaries stained for ICAM-1. Normal ovary showing strong
staining (A) in the surface epithelium and (B) in a surface invagination. (C–E) Ovarian tumours stained for ICAM-1. (C) The majority of tumour cells are positive
(D) Discrete groups of positive tumour cells. (E) A distinct pattern of staining bordering groups of tumour cells. Scale bar = 20 µ m Treatment of 8 cell lines with the de novo methyltransferase
inhibitor 5-aza-2′ -deoxycytidine dramatically increased ICAM-1
expression levels for all lines, suggesting that CpG island methyla-
tion may be a common mechanism of silencing of the ICAM-1
gene in ovarian adenocarcinoma. Extensive changes in global
DNA methylation have been found in ovarian cancers (Cheng
et al, 1997), and there is strong evidence that DNA hypermethyla-
tion plays a role in the inactivation of expression of E-cadherin,
p16, BRCA1, GPC3 and hMLH1 in ovarian adenocarcinoma (Lin
et al, 1999; McCluskey et al, 1999; Strathdee et al, 1999; Fearon,
2000). There was also frequent LOH at 19p13 (28%) at a similar
rate to that reported in previous studies (Amfo et al, 1995; Wang 
et al, 1999). We found a weak association between this LOH and
loss of ICAM-1 expression, suggesting that loss of expression may
also be due to LOH in some cases. 
Expression of ICAM-1 has previously been examined by
immunohistochemistry in a variety of human neoplasms including
breast cancer, lung cancer, squamous-cell carcinoma, renal cell
cancer, pancreatic cancer, gastric cancer, ovarian adenocarcinoma,
prostatic cancer, thyroid cancer and malignant melanoma (Johnson
et al, 1989; Vogetseder et al, 1989; Natali et al, 1990; Tomita et al,
1990; Koyama et al, 1992; Schwaeble et al, 1993; Ogawa et al,
1998). Previous studies which have included ovarian adenocarci-
nomas scored either 5–30% of cells positive from a single tumour
examined (Vogetseder et al, 1989) or found 0/15 primary tumours
and 0/9 metastasis positive for ICAM-1 expression (Natali et al,
1990). While the antibody used in these studies was different to
that used in this study, the data support our findings that the
majority of ovarian tumours express little or no ICAM-1. 
Some studies have found a positive correlation between ICAM-
1 expression and metastatic disease in malignant melanoma
(Johnson et al, 1989; Natali et al, 1990) and gastric cancer
(Koyama et al, 1992). It is postulated that ICAM-1 expression on
tumour cells may mediate their attachment to activated leukocytes,
promote the migration of individual cells away from the primary
tumour and enhance endothelial binding, extravasation and inva-
sion into surrounding tissues (Johnson, 1991). In contrast, other
investigators have reported a negative correlation between ICAM-
1 expression and tumour growth and metastasis in colorectal
cancer and breast cancer and found that patients with ICAM-1-
positive tumours had a better prognosis than those whose tumours
did not (Shibata et al, 1996; Ogawa et al, 1998). These findings
may be a reflection of the different tumour backgrounds. Using the
same scoring system for ICAM-1 expression as other investigators
(Ogawa et al, 1998), we have also found that patients whose
tumours expressed ICAM-1 had improved survival. However, as
this observation is based on only 20 primary ovarian adenocarci-
nomas, it needs to be verified by larger independent studies. 
The presence of ICAM-1 on the tumour cells may make them
more susceptible to cellular immunity and indeed a significant
correlation has been observed between ICAM-1 expression on
tumour cells and the degree of mononuclear infiltration (Tomita
et al, 1990). A number of studies have been conducted to deter-
mine the function of ICAM-1 on tumour cells in vivo. Transfection
of the human ICAM-1 gene into various cancer cells lines using
plasmid or viral vectors resulted in decreased tumorigenicity when
injected into mouse or rat hosts (Burno et al, 1995; Wei et al, 1996;
Uzendoski et al, 1997; D’Angelica et al, 1999; Kikuchi et al,
1999). Several lines of evidence demonstrate that this protection
was due, at least in part, to activation of cellular immunity by
ICAM-1 (Burno et al, 1996; Wei et al, 1996; Uzendoski et al,
1997; D’Angelica et al, 1999). Therefore, while more investiga-
tion is required to determine the significance of the reduced
ICAM-1 expression levels in ovarian cancer, evidence from other
models suggests that ICAM-1 gene transfer may be of value for the
immunotherapy of ovarian cancer. 
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